Skip to main content

Table 1 Patient Characteristics in Cavitary and Noncavitary Adenocarcinoma with EGFR mutations

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Characteristic All patients
N = 276
Cavity
N = 15
Noncavity
N = 261
P
Age, Median (range), y 61 (26–86) 61 (37–76) 61 (26–86) 0.271
 ≤65 178 (64.5) 12 (80.0) 166 (63.6)  
 > 65 98 (35.5) 3 (20.0) 95 (36.4)  
Gender, no. (%)     0.008
 Male 96 (34.8) 10 (66.7) 86 (33.0)  
 Female 108 (65.2) 5 (33.3) 175 (67.0)  
Smoking history, no. (%)     0.494
 Nonsmokers 224 (81.2) 11 (73.3) 213 (81.6)  
 Former or current smokers 52 (18.8) 4 (26.7) 48 (18.4)  
ECOG PS, no. (%)     0.377a
 0 10 (3.6) 1 (6.7) 9 (3.4)  
 1 242 (87.7) 14 (93.3) 228 (87.4)  
 2 20 (7.2) 0 (0.0) 20 (7.7)  
 3 4 (1.4) 0 (0.0) 4 (1.5)  
TNM stage, no. (%)     0.478b
 Recurrent 14 (5.1) 1 (6.7) 13 (5.0)  
 IIIB 31 (11.2) 0 (0.0) 31 (11.9)  
 IV 231 (83.7) 14 (93.3) 217 (83.1)  
T stage, no. (%)     0.270
 T1–2 101 (36.6) 5(33.3) 96 (36.8)  
 T3–4 175 (63.4) 10 (66.7) 165 (63.2)  
N stage, no. (%)     0.532
 N0–1 64 (23.2) 2 (13.3) 62 (23.8)  
 N2–3 212 (76.8) 13 (86.7) 199 (76.2)  
Mean tumor size (cm), ±SD 3.73 ± 1.74 2.87 ± 0.99 3.76 ± 1.76 0.056
Brain metastasis, no. (%) 71 (25.7) 4 (26.7) 67 (25.7) 1.000
Liver metastasis, no. (%) 17 (6.2) 1 (6.7) 16 (6.1) 1.000
Bone metastasis, no. (%) 116 (42.0) 8 (53.3) 108 (41.4) 0.362
EGFR-TKI, no. (%)     0.537c
 Gefitinib 185 (67.0) 9 (60.0) 176 (67.4)  
 Erlotinib 45 (16.3) 2 (13.3) 43 (16.5)  
 Icotinib 44 (15.9) 4 (26.7) 40 (15.3)  
 Afatinib/Osimertinib 2 (0.8) 0 (0.0) 2 (0.8)  
EGFR mutations, no. (%)     0.362d
 Exon 19 deletion 117 (42.4) 9 (60.0) 108 (41.4)  
 L858R mutation 130 (47.1) 6 (40.0) 124 (47.5)  
 Raree 29 (10.5) 0 (0.0) 29 (11.1)  
  1. Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, ECOG PS Eastern Corporation Oncology Group performance status, SD standard deviation
  2. aECOG PS 0 or 1 vs. 2 or 3
  3. bRecurrent/IIIB vs. Stage IV
  4. cGefitinib vs. Other EGFR-TKIs
  5. dExon 19 deletion vs. others
  6. eincluding EGFR mutations in exons 18 and 20, other than 19DEL and L858R mutations